WCN26-2320 Ultra-low-dose Rituximab is Effective for the Treatment of Patients with Minimal Change Disease - A Retrospective Study

Read full text Summarise with VIRAT
Authors: Chang Wang, Bing Li
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Rituximab (RTX), an anti-CD20 monoclonal antibody, can effectively treat minimal change disease (MCD), with low toxicity and a reduced steroid dosage. The optimal dosage of RTX for treating MCD remains unclear. This study aimed to investigate the efficacy of an ultra-low-dose regimen of RTX (100 mg per week for 4 weeks) for treating MCD.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105995–105995
Publication date
25 March 2026
Language
EN